Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,394 result(s) found. Displaying page 2,209 of 2,220.
    «« First « Previous 2205  2206  2207  2208  2209  2210  2211  2212  2213  Next» Last»»
    EudraCT Number: 2020-005035-70 Sponsor Protocol Number: CKAE609B12201 Start Date*: 2025-12-02
    Sponsor Name:Novartis Pharma AG
    Full Title: An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) ...
    Medical condition: Severe Plasmodium falciparum Malaria
    Disease: Version SOC Term Classification Code Term Level
    26.0 10021881 - Infections and infestations 10069722 Complicated malaria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016267-11 Sponsor Protocol Number: C09-30 Start Date*: 2009-10-23
    Sponsor Name:Inserm
    Full Title: Etude des réponses immunitaires après vaccination anit-influenza saisonnier et anti-H1N1 variant pandémique dans une population de personnel soignant.
    Medical condition: symptome de la grippe
    Disease: Version SOC Term Classification Code Term Level
    12.0 10016797 Flu-like symptoms LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-007481-38 Sponsor Protocol Number: C07-25 Start Date*: 2008-04-15
    Sponsor Name:INSERM
    Full Title: Effet d'un antagoniste du récepteur de l'endothéline 1 (Sitaxentan, Thelin) sur le remodelage bronchique au cours de l'asthme sévère avec obstruction bronchique persistante.
    Medical condition: asthme persistant modéré à sévère
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003554 Asthma aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004402-13 Sponsor Protocol Number: C08-01 Start Date*: 2009-03-17
    Sponsor Name:Inserm
    Full Title: Etude en neuropsychologie, imagerie fonctionnelle et pharmacologie des effets cognitifs chez l'enfant épileptique traité par le topiramate ou le clobazam
    Medical condition: Epilepsie partielle crypotgénique/ symptomatique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001431-56 Sponsor Protocol Number: NUT-2/PBC Start Date*: 2022-03-07
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patien...
    Medical condition: primary biliary cholangitis
    Disease: Version SOC Term Classification Code Term Level
    27.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) FI (Prematurely Ended) BE (Completed) FR (Completed) NO (Prematurely Ended) NL (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004410-42 Sponsor Protocol Number: C11-09 Start Date*: 2012-11-26
    Sponsor Name:Inserm
    Full Title: A phase I/II, open labeled, monocentric study of direct intracranial administration of a replication deficient adeno-associated virus gene transfer vector serotype rh.10 expressing the human ARSA c...
    Medical condition: Early onset forms of MLD
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    14.1 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001219-53 Sponsor Protocol Number: TR11 Start Date*: 2019-03-06
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRI...
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000974-22 Sponsor Protocol Number: C06-46 Start Date*: 2008-01-23
    Sponsor Name:Inserm
    Full Title: Essai thérapeutique de phase II séquentiel non randomisé non contrôlé, multicentrique de traitement par everolimus de la maladie de Kaposi classique ou endémique.
    Medical condition: Maladie de Kaposi classique ou endémique
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023287 Kaposi's sarcoma classical LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002198-30 Sponsor Protocol Number: EPICURESUB05T02 Start Date*: 2007-07-03
    Sponsor Name:Inserm-ISP Pole Recherches cliniques et thérapeutiques
    Full Title: A MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AT THE MAXIMAL TOLERATED DOSAGE, AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH...
    Medical condition: Dravet Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10054859 Myoclonic epilepsy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000468-41 Sponsor Protocol Number: CCDZ173X2201E1 Start Date*: 2016-07-19
    Sponsor Name:Pharming Technologies B.V.
    Full Title: An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinos...
    Medical condition: APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Prematurely Ended) IE (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2025-000542-25 Sponsor Protocol Number: B7471024 Start Date*: 2026-03-09
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN IN A SERIES OF 3 INFANT DOSES AND 1 TODDLER DOSE IN INFANTS I...
    Medical condition: Pneumococcal Disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2026-000021-16 Sponsor Protocol Number: VLA1553-321 Start Date*: 2026-03-03
    Sponsor Name:Instituto Butantan (Principal Sponsor in Brazil) [...]
    1. Instituto Butantan (Principal Sponsor in Brazil)
    2. Valneva Austria GmbH (Development lead and Co-Sponsor)
    Full Title: A Multicenter, Randomized, Controlled, Double Blinded Pivotal Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Adolescents Aged 12 Y...
    Medical condition: healthy volunteers active immunization for the prevention of Chikungunya virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10067256 Chikungunya virus infection PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-001594-24 Sponsor Protocol Number: CABL001E2201 Start Date*: 2018-10-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treat...
    Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) DK (Completed) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2018-000151-40 Sponsor Protocol Number: SGM-CLIN03 Start Date*: 2019-06-13
    Sponsor Name:Surgimab
    Full Title: Multicenter, semi-blinded, randomized, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for t...
    Medical condition: Patients undergoing curative surgery for colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003235-23 Sponsor Protocol Number: RBM 04-34 Start Date*: 2009-01-09
    Sponsor Name:Inserm
    Full Title: Essai randomisé multicentrique de phase II d'évaluation immunologique d'une stratégie vaccinale de type "prime boost" associant une administration du vaccin conjugué anti-pneumococcique à S0 suivie...
    Medical condition: Déficit immunitaire commun variable
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010112 Common variable immunodeficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004024-12 Sponsor Protocol Number: STO-304-LOR-0092-I Start Date*: 2005-04-05
    Sponsor Name:Technical University of Munich
    Full Title: Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma
    Medical condition: advanced gastro-oesophageal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001456-34 Sponsor Protocol Number: ArgatrobanECMO_1.2 Start Date*: 2021-07-08
    Sponsor Name:Medical University of Vienna
    Full Title: A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)
    Medical condition: patients requiring treatment with extracorporeal membrane oxygenation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006647-31 Sponsor Protocol Number: ASSO OE-1 Start Date*: 2007-08-03
    Sponsor Name:The Austrian Society of Surgical Oncology (ACO-ASSO)
    Full Title: p53-Adjusted Neoadjuvant Chemotherapy for potentially resectable Oesophageal Cancer "pANCHO".
    Medical condition: Interaction between a predictive marker and response to induction chemotherapy in patients with potentially resectable esophageal cancer Predictive Marker Trial
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015362 Esophageal cancer LLT
    Population Age: Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005328-18 Sponsor Protocol Number: P030444 Start Date*: 2007-05-22
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude prospective, randomisée, en double aveugle versus placebo, internationale, groupe parallèle, évaluant l'efficacité et la sécurité d'un bolus I.V de tenecteplase en comparaison avec un traitem...
    Medical condition: -Patients atteints d'embolie pulmonaire de gravité intermédiaire
    Disease: Version SOC Term Classification Code Term Level
    8.1 10014521 pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) PT (Completed) AT (Completed) GR (Completed) ES (Completed) BE (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002526-23 Sponsor Protocol Number: 68GaPET-Meningioma-2013 Start Date*: 2014-02-12
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas
    Medical condition: Based on the finding that meningiomas express somatostatin-receptor 2 (SSTR2), PET imaging with SSTR ligands like 68Ga-DOTATOC has been proposed as a more specific method. Currently, the role of SS...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2205  2206  2207  2208  2209  2210  2211  2212  2213  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 26 19:20:53 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA